

Hyun Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7767490/publications.pdf>

Version: 2024-02-01

39
papers

2,120
citations

393982

19
h-index

301761

39
g-index

41
all docs

41
docs citations

41
times ranked

2130
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Image Analysis at Chronic Lung Allograft Dysfunction Onset Predicts Mortality. Transplantation, 2022, 106, 1253-1261.	0.5	6
2	The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An observation from the Scleroderma Lung Study II Cohort. Journal of Scleroderma and Related Disorders, 2022, 7, 117-127.	1.0	3
3	Procedural outcomes associated with use of the AngioVac System for right heart thrombi: A safety report from RAPID registry data. Vascular Medicine, 2022, 27, 277-282.	0.8	11
4	Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease. Rheumatology, 2022, 61, 4702-4710.	0.9	11
5	Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. ACR Open Rheumatology, 2021, 3, 8-16.	0.9	7
6	The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110042.	1.0	10
7	End-to-end domain knowledge-assisted automatic diagnosis of idiopathic pulmonary fibrosis (IPF) using computed tomography (CT). Medical Physics, 2021, 48, 2458-2467.	1.6	3
8	Endovascular Removal of Thrombus and Right Heart Masses Using the AngioVac System: Results of 234 Patients from the Prospective, Multicenter Registry of AngioVac Procedures in Detail (RAPID). Journal of Vascular and Interventional Radiology, 2021, 32, 549-557.e3.	0.2	39
9	Reproducibility of lung nodule radiomic features: Multivariable and univariable investigations that account for interactions between CT acquisition and reconstruction parameters. Medical Physics, 2021, 48, 2906-2919.	1.6	16
10	A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images. Contemporary Clinical Trials, 2021, 104, 106333.	0.8	3
11	Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 1301-1310.	2.9	104
12	Examining Diversity: a Content Analysis of Cancer Depictions on Primetime Scripted Television. Journal of Cancer Education, 2021, , 1.	0.6	0
13	Evaluating Size-Specific Dose Estimate (SSDE) as an estimate of organ doses from routine CT exams derived from Monte Carlo simulations. Medical Physics, 2021, 48, 6160-6173.	1.6	7
14	The Extent and Diverse Trajectories of Longitudinal Changes in Rheumatoid Arthritis Interstitial Lung Diseases Using Quantitative HRCT Scores. Journal of Clinical Medicine, 2021, 10, 3812.	1.0	5
15	Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis and Rheumatology, 2020, 72, 316-325.	2.9	14
16	Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups. European Radiology, 2020, 30, 726-734.	2.3	38
17	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine, the, 2020, 8, 963-974.	5.2	348
18	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. ACR Open Rheumatology, 2020, 2, 362-370.	0.9	31

#	ARTICLE	IF	CITATIONS
19	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 963-967.	1.6	3
20	Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. <i>Open Respiratory Medicine Journal</i> , 2020, 14, 22-31.	1.3	21
21	A Qualitative Evaluation of Impact and Implementation of a Theater-Based Sexual Health Intervention in Los Angeles High Schools. <i>American Journal of Sexuality Education</i> , 2019, 14, 269-291.	0.7	1
22	Wireless Emergency Alert messages: Influences on protective action behaviour. <i>Journal of Contingencies and Crisis Management</i> , 2019, 27, 374-386.	1.6	33
23	Prediction of progression in idiopathic pulmonary fibrosis using CT scans at baseline: A quantum particle swarm optimization - Random forest approach. <i>Artificial Intelligence in Medicine</i> , 2019, 100, 101709.	3.8	22
24	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019, 71, 2059-2067.	2.9	55
25	Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Radiology</i> , 2019, 292, 103-109.	3.6	10
26	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. <i>Journal of Rheumatology</i> , 2019, 46, 1316-1325.	1.0	23
27	Determining progression of scleroderma-related interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 62-70.	1.0	12
28	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 644-652.	2.5	77
29	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1286-1295.	1.5	74
30	Free-breathing quantification of hepatic fat in healthy children and children with nonalcoholic fatty liver disease using a multi-echo 3-D stack-of-radial MRI technique. <i>Pediatric Radiology</i> , 2018, 48, 941-953.	1.1	35
31	Estimating organ doses from tube current modulated CT examinations using a generalized linear model. <i>Medical Physics</i> , 2017, 44, 1500-1513.	1.6	12
32	How Urban Youth Perceive Relationships Among School Environments, Social Networks, Self-Concept, and Substance Use. <i>Academic Pediatrics</i> , 2017, 17, 161-167.	1.0	8
33	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease. <i>Chest</i> , 2017, 151, 813-820.	0.4	54
34	Accelerated ferumoxytol-enhanced 4D multiphase, steady-state imaging with contrast enhancement (MUSIC) cardiovascular MRI: validation in pediatric congenital heart disease. <i>NMR in Biomedicine</i> , 2017, 30, e3663.	1.6	30
35	Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. <i>PLoS ONE</i> , 2017, 12, e0187580.	1.1	58
36	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	5.2	754

#	ARTICLE	IF	CITATIONS
37	Blood-Labyrinth Barrier Permeability in Menière Disease and Idiopathic Sudden Sensorineural Hearing Loss: Findings on Delayed Postcontrast 3D-FLAIR MRI. American Journal of Neuroradiology, 2016, 37, 1903-1908.	1.2	67
38	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Research and Therapy, 2015, 17, 372.	1.6	87
39	Determining the Variability of Lesion Size Measurements from CT Patient Data Sets Acquired under "No Change" Conditions. Translational Oncology, 2015, 8, 55-64.	1.7	26